Post by
retiredcf on May 28, 2021 8:35am
Canaccord
Well below the concensus but still 32% above our current SP. . GLTA
Though its first-quarter earnings fell below expectations, Canaccord Genuity analyst Derek Dley said Cresco Labs Inc. exhibited “solid” top-line growth and is positioned for further expansion. However, he trimmed his target to $19 from $22, falling short of the $23.12 average, with a “speculative buy” rating.
“In our view, Cresco is well positioned to capitalize on the increasing acceptance of cannabis within its core states, boasts a best-in-class management team, and offers investors a differentiated cannabis opportunity through its focus on both wholesale and retail,” said Mr. Dley.
Be the first to comment on this post